Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACEMATE: Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
NCT06230354Phase 2Active, not recruiting
- Sponsor
- Imperial College London
- Start
- May 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Proportion of participants who are in remission at 24 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT06230354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230354.